Emergent Biosolutions Inc (EBS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has a cash flow conversion efficiency ratio of 0.164x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($56.10 Million) by net assets ($341.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Emergent Biosolutions Inc (EBS) market capitalisation for the company's overall valuation and market capitalisation.
Emergent Biosolutions Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Emergent Biosolutions Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Emergent Biosolutions Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emergent Biosolutions Inc ranked by their cash flow conversion efficiency. Explore how high is Emergent Biosolutions Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
High Tide Inc
V:HITI
|
0.043x |
|
Samsung C and T 1P Pref
KO:02826K
|
0.026x |
|
Empire Energy Group Ltd
AU:EEG
|
0.012x |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
0.000x |
|
Smart Sand Inc
NASDAQ:SND
|
0.014x |
|
Fourlis Holdings S.A.
AT:FOYRK
|
0.155x |
|
Stellar V Capital Corp. Unit
NASDAQ:SVCCU
|
0.000x |
|
Grupo Industrial Saltillo S.A.B. de C.V
MX:GISSAA
|
0.008x |
Annual Cash Flow Conversion Efficiency for Emergent Biosolutions Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Emergent Biosolutions Inc from 2004 to 2025. View EBS share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.60 Million | $170.60 Million | 0.326x | +168.50% |
| 2024-12-31 | $482.80 Million | $58.70 Million | 0.122x | +138.27% |
| 2023-12-31 | $649.30 Million | $-206.30 Million | -0.318x | -1192.99% |
| 2022-12-31 | $1.39 Billion | $-34.10 Million | -0.025x | -112.33% |
| 2021-12-31 | $1.61 Billion | $321.10 Million | 0.199x | -46.30% |
| 2020-12-31 | $1.45 Billion | $536.90 Million | 0.371x | +114.83% |
| 2019-12-31 | $1.09 Billion | $188.00 Million | 0.173x | +317.70% |
| 2018-12-31 | $1.01 Billion | $41.80 Million | 0.041x | -81.88% |
| 2017-12-31 | $912.35 Million | $208.14 Million | 0.228x | +154.30% |
| 2016-12-31 | $596.21 Million | $53.49 Million | 0.090x | +33.18% |
| 2015-12-31 | $660.02 Million | $44.46 Million | 0.067x | -66.82% |
| 2014-12-31 | $553.20 Million | $112.32 Million | 0.203x | +2.42% |
| 2013-12-31 | $489.17 Million | $96.97 Million | 0.198x | +121.08% |
| 2012-12-31 | $442.13 Million | $39.64 Million | 0.090x | +156.05% |
| 2011-12-31 | $416.73 Million | $14.59 Million | 0.035x | -86.86% |
| 2010-12-31 | $373.56 Million | $99.54 Million | 0.266x | +112.94% |
| 2009-12-31 | $243.81 Million | $30.51 Million | 0.125x | +240.94% |
| 2008-12-31 | $199.35 Million | $7.32 Million | 0.037x | -88.67% |
| 2007-12-31 | $171.16 Million | $55.45 Million | 0.324x | +1204.61% |
| 2006-12-31 | $138.47 Million | $-4.06 Million | -0.029x | -104.15% |
| 2005-12-31 | $59.74 Million | $42.25 Million | 0.707x | +76.50% |
| 2004-12-31 | $22.95 Million | $9.20 Million | 0.401x | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more